



Attorney Dr. No. 032475-032 Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#2 ✓

In re Patent Application of

Andre Delacourte et al.

Application No.: 10/526,899

Filing Date: March 7, 2005

Title: MEANS FOR DETECTING NEURODEGENERATIVE PROCESSES AND THEIR APPLICATIONS

Group Art Unit:

Examiner:

Confirmation No.:

FIRST
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a FIRST Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of _____ is enclosed for the fee due.
- ☐ Charge _____ to credit card. Form PTO-2038 is attached.


The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

By


Erin M. Dunston
Registration No. 51,147

Date: May 11, 2005

(8/04)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
Andre Delacourte <i>et al.</i>)	Group Art Unit:
Application No.: 10/526,899)	Examiner:
Filed: March 7, 2005)	Confirmation No.:
For: MEANS FOR DETECTING)	
NEURODEGENERATIVE PROCESSES))	
AND THEIR APPLICATIONS)	

FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,
BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date May 11, 2005

By: 

Erin M. Dunston
Registration No. 51,147

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Application Number

10/5 1999

Filing Date

March 7, 2005

First Named Inventor


Andre Delacourte et al.

Examiner Name

Attorney Docket Number

032475-032

MAY 11 2005



U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
	6,444,431	B1	Moser <i>et al.</i>	09-03-2002

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	CHANG, Sun Young <i>et al.</i> , "Interaction of the C-Terminal Domain of p43 and the Alpha Subunit of ATP Synthase - Its Functional Implication in Endothelial Cell Proliferation," 277(10) JOURNAL OF BIOLOGICAL CHEMISTRY 8388-8394 (March 8, 2002)
	KAGAWA Y. <i>et al.</i> , "Regulation of Mitochondrial ATP Synthesis in Mammalian Cells by Transcriptional Control" 22(3) INTERNATIONAL JOURNAL OF BIOCHEMISTRY 219-229 (1990)
	KIM S.H. <i>et al.</i> , "Decreased Levels of Complex III Core Protein 1 and Complex V beta chain in Brains from Patients with Alzheimer's Diseases and Down Syndrome," 57(12) CMLS CELLULAR AND MOLECULAR LIFE SCIENCES 1810-1816 (NOVEMBER 2000)
	LEFEBVRE-LEGENDRE, L. <i>et al.</i> , "Identification of a Nuclear Gene (FMC1) Required for the Assembly/Stability of Yeast Mitochondrial F ₁ -ATPase in Heat Stress Conditions," 276(9) JOURNAL OF BIOLOGICAL CHEMISTRY (March 2, 2001)
	MOSER T. <i>et al.</i> , "Angiostatin Binds ATP Synthase on the Surface of Human Endothelial Cells," 96(6) PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, National Academy of Science, Washington, US (March 16, 1999)
	SCHÄGGER H. <i>et al.</i> , "Human Diseases with Defects in Oxidative Phosphorylation 2. F ₁ F ₀ ATP-Synthase Defects in Alzheimer Disease Revealed by Blue Native Polyacrylamide Gel Electrophoresis," 227(3) EUROPEAN JOURNAL OF BIOCHEMISTRY/FEBS GERMANY (February 1, 1995)

Examiner Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.